Press Releases

 
Press Releases
  Date Title View
Mar 20, 2017
BERKELEY, CA -- (Marketwired) -- 03/20/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will be presenting data on three programs based on stimulation of the immune response using Toll-Like Receptor 9 (TLR9) agonists at the 2017 American Association for Cancer Research Annual Meeting in Washington, D.C. from April 1-5,...
Mar 13, 2017
BERKELEY, CA -- (Marketwired) -- 03/13/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2016. The net loss for the year ended December 31, 2016 was $112.4 million, or $2.92 per share, compared to $106.8 million, or $3.25 per share, for the year ended Decemb...
Mar 6, 2017
BERKELEY, CA -- (Marketwired) -- 03/06/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-P...
Mar 2, 2017
BERKELEY, CA -- (Marketwired) -- 03/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference next week in Boston, MA. The presentation will be webcast live and will occur on Monday, March 6, 2017 at 1:20 p.m....
Feb 28, 2017
BERKELEY, CA -- (Marketwired) -- 02/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Dynavax's responses to the Complete Response Letter (CRL) issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the company's vaccin...
Feb 16, 2017
BERKELEY, CA -- (Marketwired) -- 02/16/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Michael Ostrach, Dynavax's senior vice president and chief financial officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York, NY. The presentation will be webcast live and will occur on ...
Jan 9, 2017
BERKELEY, CA -- (Marketwired) -- 01/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will present at the J.P. Morgan 35th Annual Healthcare Conference this week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 12, 2016 at 8:30...
Jan 5, 2017
BERKELEY, CA -- (Marketwired) -- 01/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage biopharmaceutical company, today announced that it is reshaping its strategy and operations to prioritize its emerging clinical and preclinical immuno-oncology portfolio. The company has implemented significant organizational restructurin...
Dec 5, 2016
BERKELEY, CA -- (Marketwired) -- 12/05/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2, two-part clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lymphoma. The combination of intratumoral SD-101 and low-dose irradiation resulted in tumor regr...
Dec 1, 2016
BERKELEY, CA -- (Marketwired) -- 12/01/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Inv...
1
...
NextLast
= add release to Briefcase